A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma

A Phase IIa open label study evaluating the preliminary efficacy of intratumoural tigilanol tiglate in advanced and/or metastatic soft tissue sarcoma of the extremities and body wall.

Trial Details

NCT ID
NCT05755113
Phase
PHASE2
Sponsor
QBiotics Group Limited
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Tigilanol Tiglate
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Are willing and able to provide written informed consent for the study prior to any protocol-specific procedures and to comply with all local and s…
  • Are ≥ 18 years of age on the day of providing informed consent.
  • Have advanced and/or metastatic disease of the body wall or extremities that is amenable to intratumoural injection either by palpation or under ul…
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →